tuhurabio.com - HURA Operating profit EBITDA
TuHURA Biosciences, Inc. (HURA) bases its development of targeted cancer immunotherapy on external financing due to a lack of current sales. Geopolitical instability complicates international trials and reagent supplies, a trend captured by the EBITDA dynamics displayed in this chart from GURU.Markets, where the 0.00 level reflects the current state. The issuer's future revenues rely on the rollout of innovative vaccines for insurance companies.
TuHURA Biosciences Inc. - analytical breakdowns and key metrics (HURA)
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Aggregate Debt to Capital TuHURA Biosciences, Inc.|HURA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital TuHURA|HURA - Company Aggregate Debts|Debt to Net Assets Ratio TuHURA|HURA - Company Long-Term Liabilities|Company Short-Term Debts TuHURA Biosciences|Intermediate Coverage Ratio tuhurabio.com
- earnings and market ratios statistics:
HURA - Net Profit|Projected Future Earnings TuHURA Biosciences, Inc.|HURA - Price to Earnings Ratio|Future Price to Earnings Multiple TuHURA|HURA - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TuHURA Biosciences, Inc.|HURA - Operating profit EBITDA|Net earnings per share for the last four quarters TuHURA Biosciences|HURA - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months tuhurabio.com|HURA - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year TuHURA Biosciences, Inc.
- sales revenue and business income indicators:
Summary company analytics:TuHURA Biosciences Inc.
This indicator measures actual cash inflow from core operations, stripping the financial result of non-cash GAAP adjustments to reveal true operational efficiency. Analysis based on aggregated EBITDA allows for tracking the actual liquidity of TuHURA Biosciences (HURA), which is critical given the full outsourcing of manufacturing and clinical trials that eliminates capital expenditures for proprietary facilities.
Competitor analysis for TuHURA Biosciences, Inc.
Operating profit EBITDA beigene.com ONC|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Corp - Income before deduction of interest, taxes and amortization|URGN (UroGen Pharma Ltd) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Therapeutics Inc. BCAX|Profit before payment of interest, taxes and amortization Personalis, Inc. (PSNL)|ERAS - Profit before interest, taxes and amortization|Operating profit EBITDA DCTH (delcath.com)|Operating profit before depreciation charges Y-mAbs Corp|AURA - Profit before payment of interest, taxes and amortization|CADL (candeltx.com) - Operating profit before amortization|ARAY (accuray.com) - Operating profit before deduction of amortization|SELLAS Life Sciences Group Inc. (SLS) - Operating profit EBITDA|ACTU (Actuate Therapeutics Inc.) - Operating profit EBITDA|Operating profit EBITDA Citius Oncology Inc|Profit before payment of interest, taxes and amortization Protara Therapeutics (TARA)|Company profit before taxes, interest and amortization FATE|Operating profit EBITDA WHWK (aadibio.com)|Company profit before taxes, interest and amortization TCRX (TScan)|CSBR - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization XBIT (XBiotech Inc)|cel-sci.com (CVM) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization OSTX (OS Therapies Incorporated)|Profit before payment of interest, taxes and amortization Radiopharm Theranostics Ltd|Profit before interest, taxes and amortization Artiva Biotherapeutics ARTV|Operating profit EBITDA ANL|VERU - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Tempest Therapeutics TPST|xiliotx.com (XLO) - Profit before interest, taxes and amortization|RENB: Operating profit before deduction of amortization|Operating profit before depreciation charges Mural Oncology PLC (MURA)|KAPA (Kairos Pharma Inc) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization OnKure Therapeutics Inc (OKUR)|GDTC (CytoMed Therapeutics Ltd) - Operating profit EBITDA|Operating profit before deduction of amortization Curis, Inc. (CRIS)|Operating profit EBITDA APLM|Company profit before taxes, interest and amortization THAR|Operating profit EBITDA ADVB (advanbiomed.com)|GNPX - Operating profit before deduction of amortization|CLDI: Operating profit before deduction of amortization|SBFM - Operating profit EBITDA|Xenetic Biosciences (XBIO) - Profit before payment of interest, taxes and amortization|SLRX: Company profit before taxes, interest and amortization|PPBT (Purple Biotech Ltd) - Operating profit EBITDA|Profit before interest, taxes and amortization American Oncology Network, Inc. AONC|Operating profit EBITDA BGNE|Operating income before deduction of amortization Checkpoint Therapeutics|Elevation Oncology, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA iCAD, Inc. ICAD|Ikena Oncology, Inc. - Operating profit EBITDA|NTBL - Operating profit EBITDA|VIRX (Viracta Therapeutics) - Operating profit before deduction of amortization|MorphoSys AG - Income before deduction of interest, taxes and amortization|NAYA (NAYA Biosciences Corp) - Operating profit EBITDA|Operating profit EBITDA Ascentage Pharma Group International
